amicus therapeutics inc (FOLD:NASDAQ GM)

Executive Profile*

Background*

Mr. John F. Crowley has been Chief Executive Officer at Amicus Therapeutics Inc. since August 15, 2011. Mr. Crowley served as the Chief Executive Officer of Amicus Therapeutics Inc. from January 2005 to April 2011. Mr. Crowley founded Orexigen Therapeutics and served as its President & Chief Executive Officer from September 2003 to January 2005. Mr. Crowley served as the President of Amicus Therapeutics Inc. from January 2005 to February 18, 2011. He served as Senior ... Vice President at Genzyme Therapeutics until December 2002. Mr. Crowley founded Novazyme Pharmaceuticals Inc. and served as its Chief Executive Officer & President from March 2000 to September 2001. He was responsible for the Drug Development Strategy and Planning, Manufacturing Strategy, Planning and Oversight, Clinical and Regulatory Development, P&L Management and Accountability, Merger Integration, Business Development, Investor Relations. Mr. Crowley served in several Senior Management roles with the Bristol-Myers Squibb Company, including Director of Business Strategy for the U.S. Pharmaceuticals Group and Director of U.S. Area Marketing for the Neuroscience and Infectious Disease Division. He served as Business Strategy Consultant for Marakon Associates. He began his professional career as a litigation associate in the Health Care Practice Group of the Indianapolis-based law firm of Bingham Summers Welsh & Spilman. He is a dynamic biopharmaceutical executive and entrepreneur, has an impressive track record in the development and management of small and large companies. He has been Chairman at Amicus Therapeutics Inc. since August 15, 2011. He served as Executive Chairman of the Board of Amicus Therapeutics Inc. from January 2005 to April 2010. He has been a Director of Amicus Therapeutics Inc. since August 2004. He serves as a Director of ZyStor Therapeutics, Inc. He serves as a Director of BioNJ Inc. He served as a Director of EP Global Communications Inc. and Novazyme Pharmaceuticals, Inc. He serves on the Research Advisory Board of the national Muscular Dystrophy Association and on the board of directors of St. Peter's University Hospital. He served as a Member of the Advisory Board of Novazyme Pharmaceuticals, Inc. He served as a Director and a Member of Scientific Advisory Board at Semafore Pharmaceuticals, Inc. He serves as the President of the National Tay-Sachs and Allied Diseases Association. He was nominated to The United States Naval Academy in Annapolis, Maryland by both Senator Bill Bradley and Congresswoman Marge Roukema (N.J.), and there he completed three semesters of study. He earned Commandant's List honors and was ranked 2 of 36 Midshipman in his Plebe year (freshman). Mr. Crowley earned his B.S. Degree in Foreign Service in 1989 from Georgetown University's School of Foreign Service, a Juris Doctor from the University of Notre Dame Law School in 1992 and an M.B.A. from The Harvard Business School in 1997, where he was elected the class commencement speaker.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
FOLD:US	$2.52 USD	-0.025

COMPETITOR COMPENSATION